J. Oates

发表

Comparison between MRI and pathology in the assessment of tumour regression grade in rectal cancer

D. Tait, J. Tabernero, Gina Brown, 2017, British Journal of Cancer.

A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer.

T. Hickish, A. Norman, D. Tait, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer

T. Hickish, A. Norman, D. Tait, 2003, British Journal of Cancer.

The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer.

A. Norman, D. Tait, Gina Brown, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy

L. Assersohn, A. Norman, D. Cunningham, 2009, Cancer Chemotherapy and Pharmacology.

Sixty-day all-cause mortality rates in patients treated for gastrointestinal cancers, in randomised trials, at the Royal Marsden Hospital.

A. Norman, D. Cunningham, P. Ross, 2004, European journal of cancer.

Intestinal complications after chemotherapy for patients with unresected primary colorectal cancer and synchronous metastases

A. Norman, D. Tait, D. Cunningham, 2003, Gut.

Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF

T. Hickish, A. Norman, M. Nicolson, 2005, British Journal of Cancer.

Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer

D. Smith, A. Norman, D. Cunningham, 2005, British Journal of Cancer.

Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer

J. Baselga, R. Kurek, A. Wotherspoon, 2008, British Journal of Cancer.

Prognostic value of neutrophil-to-lymphocyte ratio in advanced oesophago-gastric cancer: exploratory analysis of the REAL-2 trial.

D. Cunningham, J. Bridgewater, C. Peckitt, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials

A. Norman, D. Cunningham, N. Maisey, 2005, British Journal of Cancer.

Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL)

A. Horwich, K. Last, A. Norman, 2007, Hematology.

PAN-EX: a pooled analysis of two trials of neoadjuvant chemotherapy followed by chemoradiotherapy in MRI-defined, locally advanced rectal cancer.

D. Tait, J. Tabernero, A. Wotherspoon, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

51 The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer: analysis from a prospective randomised controlled trial

A. Norman, D. Tait, D. Cunningham, 2003 .

Phase II trial evaluating capecitabine and irinotecan in patients (pts) with esophago-gastric (E-G) carcinoma having progressed or relapsed within 3 months of platinum-based chemotherapy

L. Assersohn, A. Norman, Gina Brown, 2005 .

Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan

A. Norman, D. Cunningham, T. Price, 2005, British Journal of Cancer.

Infusional 5-fluorouracil in the treatment of gastrointestinal cancers: The Royal Marsden Hospital experience.

A. Norman, D. Cunningham, P. Ross, 1997, The Journal of infusional chemotherapy.

44 Phase III trial comparing epirubicin, cisplatin and 5-FU (ECF) versus 5FU, etoposide and leucovorin (FELV) in previously untreated patients with advanced biliary cancer

A. Norman, D. Cunningham, P. Ross, 2003 .

Utility of the Follicular Lymphoma International Prognostic Index and the International Prognostic Index in Assessing Prognosis and Predicting First-Line Treatment Efficacy in Follicular Lymphoma Patients

A. Norman, A. Wotherspoon, D. Cunningham, 2009, Acta Haematologica.

randomised, multicenter phase-iii study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer: Confirmation of dose escalation : 1031

T. Hickish, A. Norman, M. Nicolson, 2003 .

305 Twelve weeks of neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation (CRT) and total mesorectal excision (TME) in MRI defined poor risk locally advanced rectal cancer resulted in promising tumour regression and rapid symptomatic relief

A. Norman, D. Tait, Gina Brown, 2003 .

Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study

이석호, 황수찬, T. Walsh, 2001, British Journal of Cancer.

Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?

A. Norman, D. Cunningham, H. Andreyev, 1998, European journal of cancer.

The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.

T. Hickish, A. Norman, M. Nicolson, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.

A. Norman, D. Cunningham, P. Clarke, 1998, Journal of the National Cancer Institute.

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

T. Hickish, A. Norman, M. Nicolson, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial.

D. Tait, A. Wotherspoon, D. Cunningham, 2010, The Lancet. Oncology.

The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancreatic adenocarcinoma. The results of a phase I/II study.

D. Cunningham, G. Brown, I. Chau, 2014, European journal of cancer.

Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data.

A. Norman, D. Cunningham, P. Ross, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.

A. Horwich, A. Norman, A. Wotherspoon, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

A multicentre phase II trial of primary chemotherapy with cisplatin and protracted venous infusion 5-fluorouracil followed by chemoradiation in patients with carcinoma of the oesophagus.

A. Padhani, A. Norman, D. Tait, 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

Analysis of KRAS, NRAS, BRAF, PIK3CA and TP53 mutations in a large prospective series of locally advanced rectal cancer patients

A. Wotherspoon, D. Cunningham, B. Glimelius, 2019, International journal of cancer.

Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial

D. Tait, J. Tabernero, C. Braconi, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial

T. Hickish, A. Norman, M. Nicolson, 1999, British Journal of Cancer.

Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.

L. Assersohn, A. Norman, D. Cunningham, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer.

A. Norman, D. Cunningham, P. Ross, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer.

A. Padhani, A. Norman, D. Cunningham, 1997, Annals of oncology : official journal of the European Society for Medical Oncology.

Dose finding and early efficacy study of gemcitabine plus capecitabine in combination with bevacizumab plus erlotinib in advanced pancreatic cancer.

D. Cunningham, I. Chau, K. Thomas, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma

L. Assersohn, A. Norman, D. Cunningham, 1999, British Journal of Cancer.

The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract

A. Norman, A. Wotherspoon, D. Cunningham, 2007, British Journal of Cancer.

Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy

A. Norman, D. Cunningham, P. Ross, 2004, British Journal of Cancer.

Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil

A. Norman, D. Cunningham, N. Tebbutt, 2003, British Journal of Cancer.

Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer

A. Norman, D. Cunningham, P. Ross, 2004, British Journal of Cancer.

miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial

M. Fassan, D. Tait, C. Braconi, 2016, Oncotarget.

The combination of a chemotherapy doublet (gemcitabine plus capecitabine) with a biologic doublet (bevacizumab plus erlotinib) in patients with advanced pancreatic adenocarcinoma: The TARGET study.

D. Cunningham, I. Chau, K. Thomas, 2010 .

Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma.

T. Hickish, A. Norman, D. Tait, 2004, Clinical colorectal cancer.

A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas.

M. Gore, A. Norman, M. Nicolson, 1997, British Journal of Cancer.

RAS mutations and cetuximab in locally advanced rectal cancer: results of the EXPERT-C trial.

D. Tait, A. Wotherspoon, D. Cunningham, 2014, European journal of cancer.

Randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric (OG) cancer: The REAL 2 trial.

A. Norman, M. Nicolson, D. Cunningham, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Matuzumab plus epirubicin, cisplatin and capecitabine (ECX) compared with epirubicin, cisplatin and capecitabine alone as first-line treatment in patients with advanced oesophago-gastric cancer: a randomised, multicentre open-label phase II study.

R. Kurek, T. Ruhstaller, M. Valladares-Ayerbes, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma

A. Riddell, A. Wotherspoon, D. Cunningham, 2009, British Journal of Cancer.

Elderly patients with fluoropyrimidine-resistant advanced colorectal cancer (CRC) derive similar benefit without excessive toxicity when treated with irinotecan monotherapy

A. Norman, D. Cunningham, P. Ross, 2004 .

A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma.

Y. Barbáchano, E. Hawkes, N. Starling, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.